Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia

被引：0

作者：

Tedeschi, Alessandra ^{[1
]}

Rossi, Davide ^{[2
]}

Coscia, Marta ^{[3
]}

Vismara, Eleonora ^{[1
]}

Petrizzi, Valeria Belsito ^{[4
]}

Orlandi, Ester ^{[5
]}

Cascavilla, Nicola ^{[6
]}

Scarfo, Lydia ^{[7
]}

Motta, Marina ^{[8
]}

Vitale, Candida ^{[3
]}

Ricci, Francesca ^{[1
]}

De Paoli, Lorenzo ^{[2
]}

D'Arco, Alfonso Maria ^{[4
]}

Gallamini, Andrea ^{[9
]}

Gaidano, Gianluca ^{[10
]}

Morra, Enrica ^{[1
]}

Massaia, Massimo ^{[3
]}

Montillo, Marco ^{[1
]}

机构：

[1] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy

[2] Amedeo Avogadro Univ, Dept Hematol, Novara, Italy

[3] Univ Turin, Dept Med & Expt Oncol, Sect Hematol, Turin, Italy

[4] Nocera Inferiore Hosp, Dept Internal Med, Nocera Inferiore, Italy

[5] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[6] IRCCS, Dept Hematol, San Giovanni Rotondo, Italy

[7] Ist Sci San Raffaele, Lymphoma Unit, Dept Oncohematol, Milan, Italy

[8] Brescia Hosp, Spedali Civili, Dept Hematol, Brescia, Italy

[9] Santa Croce Hosp, Dept Hematol, Cuneo, Italy

[10] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Div Hematol, Novara, Italy

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.2898.2898

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2898

引用

页数：2

共 50 条

[21] Acalabrutinib vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13
[22] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
[23] Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
Kath, R
Blumenstengel, K
Fricke, HJ
Höffken, K
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (01) : 48 - 54
[24] Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia
R. Kath
K. Blumenstengel
H. J. Fricke
K. Höffken
Journal of Cancer Research and Clinical Oncology, 2001, 127 : 48 - 54
[25] The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia
Visco, Carlo
Finotto, Silvia
Pomponi, Fabrizio
Sartori, Roberto
Laveder, Francesco
Trentin, Livio
Paolini, Rossella
Di Bona, Eros
Ruggeri, Marco
Rodeghiero, Francesco
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (04) : 289 - 293
[26] Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use
Warner, Jeremy L.
Arnason, Jon E.
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (06) : 375 - 389
[27] Alemtuzumab - A new option for refractory chronic lymphocytic leukemia?
Smith, JA
CANCER PRACTICE, 2001, 9 (04) : 211 - 213
[28] Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis
Fernando Bezares, Raimundo
Stemelin, German
Diaz, Alicia
Argentieri, Daniel
Lanari Zubiaur, Emilio
Garay, Guy
Bartomioli, Miguel
Ryser, Ricardo
Milone, Gustavo
LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1936 - 1941
[29] The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia
Brown, Jennifer R.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 110 - 118
[30] Management of relapsed/refractory Chronic Lymphocytic Leukemia
Woyach, Jennifer A.
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S11 - S18

← 1 2 3 4 5 →